CHICAGO, IL—An investigational agent given by subcutaneous injection can drastically reduce levels of lipoprotein (a), with ...

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

In the Phase 2 ALPACA study, lepodisiran significantly reduced Lp(a) levels by an average of 93.9% over the 60 to 180-day period after treatment with the highest tested dose (400 mg), meeting the ...

Lilly's lepodisiran shows a 94% reduction in heart disease risk by lowering lipoprotein(a) levels, offering a breakthrough in cardiovascular innovation.